GCM
TERN

Graham Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Graham Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,958
Closed -$443K – 1503
2025
Q4 		$443K Sell
10,958
-13,336
-55% -$308K 0.01% 674
2025
Q3 		$182K Sell
24,294
-49,674
-67% -$317K ﹤0.01% 1079
2025
Q2 		$276K Sell
73,968
-152,327
-67% -$476K ﹤0.01% 1025
2025
Q1 		$625K Buy
226,295
+93,296
+70% +$381K 0.01% 718
2024
Q4 		$737K Buy
132,999
+119,661
+897% +$810K 0.01% 588
2024
Q3 		$111K Sell
13,338
-18,771
-58% -$154K ﹤0.01% 998
2024
Q2 		$219K Buy
32,109
+1,878
+6% +$11.4K ﹤0.01% 839
2024
Q1 		$198K Buy
+30,231
New +$197K ﹤0.01% 901
2023
Q4 		– Sell
-82,978
Closed -$417K – 1324
2023
Q3 		$417K Buy
82,978
+53,998
+186% +$343K 0.01% 613
2023
Q2 		$254K Buy
+28,980
New +$338K 0.01% 745

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Graham Capital Management's TERN Position: Q1 2026 in Review

Graham Capital Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 10,958 shares — an estimated $443K sold.

Graham Capital Management first reported a position in TERN in Q2 2023 and held it in 10 quarters. The position peaked at $737K in Q4 2024. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Graham Capital Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 10,958 Terns Pharmaceuticals shares in Q1 2026, an estimated $443K.
  • Graham Capital Management first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Graham Capital Management's Terns Pharmaceuticals position peaked at $737K in Q4 2024.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.